Anavex Life Sciences Continues Dialogue With EMA To Advance Development Program Of Oral Blarcamesine In Early Alzheimer's Disease

Anavex Life Sciences Corp. (NASDAQ: AVXL) is continuing discussions with the European Medicines Agency (EMA) to advance its development program for oral blarcamesine in early Alzheimer's disease after withdrawing its marketing authorization application in the EU. The company is gathering additional data and conducting analyses to address concerns raised by the EMA's Committee for Medicinal Products for Human Use (CHMP). Additionally, Anavex is engaging with the FDA to align on the Alzheimer's development program and is also pursuing regulatory engagement for blarcamesine in Parkinson's disease and rare neurological conditions.